Pasithea shares jump 10.33% intraday after closing $60M public offering led by healthcare investors.

Pasithea Therapeutics (KTTA) surged 10.33% intraday after announcing the closing of a $60 million public offering led by healthcare-focused investors, including Vivo Capital and Janus Henderson Investors. The proceeds extended its cash runway through at least mid-2028, enabling continued development of its lead candidate, PAS-004, a MEK inhibitor for neurofibromatosis type 1 and oncology indications. The offering, priced at $0.75 per share, provided capital for clinical trials, pre-clinical studies, and corporate expansion. The news, released on December 2, 2025, reinforced investor confidence in the company’s ability to advance its pipeline and mitigate near-term liquidity risks, aligning with the stock’s sharp intraday rally.